Back
Metabolomics and its potential in drug development.
Journal article

Metabolomics and its potential in drug development.

  • Beyoğlu D Hepatology Research Group, Department of Clinical Research, Faculty of Medicine, University of Bern, Murtenstrasse 35, 3010 Bern, Switzerland. diren.beyoglu@ikp.unibe.ch
  • Idle JR
  • 2012-09-01
Published in:
  • Biochemical pharmacology. - 2013
Animals
Biomarkers
Biomarkers, Pharmacological
Clinical Trials as Topic
Drug Discovery
Drug Evaluation, Preclinical
Drug Industry
Gas Chromatography-Mass Spectrometry
Humans
Metabolomics
Spectrometry, Mass, Electrospray Ionization
Xenobiotics
English Metabolomics is the global and unbiased survey of the complement of small molecules (say, <1 kDa) in a biofluid, tissue, organ or organism and measures the end-products of the cellular metabolism of both endogenous and exogenous substrates. Many drug candidates fail during Phase II and III clinical trials at an enormous cost to the pharmaceutical industry in terms of both time lost and of financial resources. The constantly evolving model of drug development now dictates that biomarkers should be employed in preclinical development for the early detection of likely-to-fail candidates. Biomarkers may also be useful in the preselection of patients and through the subclassification of diseases in clinical drug development. Here we show with examples how metabolomics can assist in the preclinical development phases of discovery, pharmacology, toxicology, and ADME. Although not yet established as a clinical trial patient prescreening procedure, metabolomics shows considerable promise in this regard. We can be certain that metabolomics will join genomics and transcriptomics in lubricating the wheels of clinical drug development in the near future.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/71359
Statistics
Document views: 8 File downloads: